CompoAtlas

Shots Ginseng & citron miel

Integratore alimentare dichiarato in Francia, decisione del 22 maggio 2025

Shots Ginseng & citron miel (Gayelord Hauser) è un integratore alimentare dichiarato in Francia. Stato: dichiarato in Francia, commercializzazione possibile. Nessuna delle regole che verifichiamo rileva punti sulla composizione dichiarata; le dosi di vitamine e minerali non sono pubblicate da Compl’Alim e quindi non vengono controllate.

Marca
Gayelord Hauser
Responsabile dell’immissione in commercio
BJORG ET COMPAGNIE
Stato
Dichiarato in Francia, commercializzazione possibile: l’amministrazione non si è opposta alla dichiarazione (non è né un’autorizzazione né una valutazione della sicurezza)
Forma
Flacone
Dose giornaliera

30 ml

Modalità d’uso

Traduzione non disponibile. Testo originale, lingua: francese.

Prêt à boire. Agiter avant emploi.

Compl’Alim, dichiarazioni di integratori alimentari ·

Popolazioni destinatarie
Popolazione generale
Sconsigliato (secondo il fabbricante)
Donne che allattano, Bambini (sotto i 12 anni), Bambini piccoli (da 1 a 3 anni), Donne in gravidanza, Lattanti (sotto 1 anno), In trattamento con antidiabetici, Bambini (sotto i 6 anni), Bambini (sotto i 10 anni)
Obiettivi dichiarati dal fabbricante (non sono indicazioni autorizzate)
Immunità

Notifica 265923, procedura Article 15. Compl’Alim, dichiarazioni di integratori alimentari, consultato il 15 novembre 2026.

Composizione dichiarata

Piante

PiantaPartePreparazioneAl giorno
Panax ginseng C.A.Mey.RacineExtrait sec hydroalcoolique125 mg
Eleutherococcus senticosus (Rupr. et Maxim.) MaximRacineExtrait sec hydroalcoolique0,69 mg

Altri ingredienti attivi

NomeAl giorno
Propolisnon dichiarata
mielnon dichiarata

Vitamine e minerali

Compl’Alim non pubblica le dosi di vitamine e minerali. I riferimenti qui sotto permettono di leggere l’etichetta del prodotto: limite di sicurezza EFSAAutorità europea per la sicurezza alimentare. per adulti e dose massima fissata in Francia per prodotto (decreto del 9 maggio 2006, non rivisto da novembre 2006).

Forma dichiarataNutrienteLimite EFSA, adulti Dose massima in Francia
Bisglycinate de zincZinc25 mg15 mg

Additivi

E202

Altri ingredienti

jus de citron, eau

Elenco della dichiarazione, decisione dell'amministrazione del (Compl’Alim, dichiarazioni di integratori alimentari).

Il prodotto è cambiato? Fotografi la confezione.

Avvertenze dell’etichetta

Traduzione non disponibile. Testo originale, lingua: francese.

Tenir hors de portée des enfants. Déconseillée aux femmes enceintes et allaitantes. L'emploi chez les personnes sous traitement antidiabétique est déconseillé.

Compl’Alim, dichiarazioni di integratori alimentari ·

Aspetti normativi

Nessuna delle norme che verifichiamo si applica agli ingredienti notificati.

Queste informazioni riprendono la dichiarazione del fabbricante all’amministrazione (DGAL). Non dicono se il prodotto sia efficace e non sostituiscono il parere di un medico o farmacista, in particolare in gravidanza o durante un trattamento.

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

  • Panax ginseng C.A.Mey.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    PANAX GINSENG

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Vuksan et al. 2008; Seely et al. 2008; Sievenpiper et al. 2006; ESCOP 2003; Tetsutani et al. 2000; Sotaniemi et al. 1995; Chin 1991).

    Fonti citate da Health Canada (8)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Chin RKH. Ginseng and common pregnancy disorders. Asia-Oceania Journal of Obstetrics and Gynaecology 1991;17(4):379-380. PubMed
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Seely D, Dugoua JJ, Perri D, Mills E, Koren G. Safety and efficacy of Panax ginseng during pregnancy and lactation. The Canadian Journal of Clinical Pharmacology 2008;15(1):e87-e94.
    • Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Studio randomizzato
    • Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995;18(10):1373-1375. PubMed Studio clinico
    • Tetsutani T, Yamamura M, Yamaguchi T, Onoyama O, Kono M. Can red ginseng control blood glucose in diabetic patients. The Ginseng Review 2000;28:44-47.
    • Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Studio randomizzato

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, blood thinners or digoxin (Brinker 2010; Lee et al. 2008a; Dasgupta and Reyes 2005; Janetzki and Morreale 1997; Gonzalez-Seijo et al. 1995; Shader and Greenblatt 1988; Jones and Runikis 1987; Shader and Greenblatt 1985).

    Fonti citate da Health Canada (8)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dasgupta A, Reyes MA. Effect of Brazillian, Indian, Siberian, Asian, and North American ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab Fragment of antidigoxin antibody (Digiband). American Journal of Clinical Pathology 2005;124(2):229-236. PubMed
    • Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: report of a possible case. Journal of Clinical Psychopharmacology 1995;15(6):447-448. PubMed Caso clinico
    • Janetzki K, Morreale AP. Probable interaction between warfarin and ginseng. American Journal of Health-System Pharmacy 1997;54(6):692-693.
    • Jones BD, Runikis AM. Interaction of ginseng with phenelzine. Journal of Clinical Pharmacology 1987;7(3):201-202. PubMed Caso clinico
    • Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. The Journal of Alternative and Complementary Medicine 2008a;14(6):715-721. PubMed Studio randomizzato
    • Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. Journal of Clinical Psychopharmacology 1988;8(4):235. PubMed Caso clinico
    • Shader RI, Greenblatt DJ. Phenelzine and the dream machine – ramblings and reflections. Journal of Clinical Psychopharmacology 1985;5(2):65. PubMed Caso clinico

    Controindicazioni

    Condizione di applicazione: Traditional Chinese Medicine.

    Do not use in cases of yin deficiency with heat signs, heat excess, or in the absence of significant qi deficiency (Bensky et al. 2004).

    Fonti citate da Health Canada (1)
    • Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.

    Reazioni avverse note

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience insomnia, anxiety or headaches (Lee et al. 2008b; Vuksan et al 2008; de Andrade et al.2007; Sievenpiper et al. 2006; Coon and Ernst 2002; Ellis and Reddy 2002; Scaglione et al. 2001; Siegel 1979).

    Fonti citate da Health Canada (8)
    • Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Safety 2002;25(5):323-344. PubMed Revisione sistematica
    • de Andrade E, de Masquita AA, de Almeida Claro J, de Andrade PM, Ortiz V, Paranhos M, Srougi M. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian Journal of Andrology 2007;9(2):241-244.
    • Ellis JM, Reddy P. Effects of Panax ginseng on quality of life. The Annals of Pharmacotherapy 2002;36(3):375-379. PubMed Studio randomizzato
    • Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Disease and Associated Disorders 2008b;22(3):222-226. PubMed Studio randomizzato
    • Scaglione F, Weiser K, Alessandria M. Effects of the standardised ginseng extract G115 in patients with chronic bronchitis. Clinical Drug Investigation 2001;21(1):41-45.
    • Siegel RK. Ginseng abuse syndrome. Problems with the panacea. The Journal of the American Medical Association 1979;241(15):1614-1615. PubMed
    • Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Studio randomizzato
    • Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Studio randomizzato

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Monografia di Health Canada del 27 giugno 2025

  • Eleutherococcus senticosus (Rupr. et Maxim.) Maxim
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS

    Via di somministrazione: Oral (ESCOP 2003; Bradley 1992)

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    Fonti citate da Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).

    Fonti citate da Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Controindicazioni

    Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).

    Fonti citate da Health Canada (5)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Monografia di Health Canada del 31 ottobre 2025

  • Propolis
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    PROPOLIS - Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are allergic to bee products, poplar tree products, or balsam of Peru (Brinker 2010; Marcucci 1995; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Gryzwa 1983).

    Fonti citate da Health Canada (5)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie 1995;26:83-89.
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Caso clinico
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Condizione di applicazione: Relief of sore throat/mouth and throat infections.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Reazioni avverse note

    Stop use if hypersensitivity/allergy occurs (PPRC 2020; Scully 2006; Hsu et al. 2004; Teraki and Shiohara 2001; Machácková 1988; Hausen et al. 1987; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Grzywa 1983).

    Fonti citate da Health Canada (9)
    • Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy (II): the sensitizing properties of 1,1-dimethylallyl caffeic acid ester. Contact Dermatitis 1987;17:171-177. PubMed Caso clinico
    • Hsu CY, Chiang WC, Weng TI, Chen WJ, Yuan A. Laryngeal edema and anaphalactic shock after topical propolis use for acute pharyngitis. American Journal of Emergency Medicine 2004;22(5):432-433. PubMed Caso clinico
    • Machackova J. The incidence of allergy to propolis in 605 consecutive patients patch tested in Prague. Contact Dermatitis 1988;18:210-212. PubMed
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Caso clinico
    • PPRC 2020: Pharmacopoeia of the People's Republic of China, Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People's Republic of China; 2020.
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Scully C. Propolis: A background (Letter). British Dental Journal 2006;200(7):359-360. PubMed
    • Teraki Y, Shiohara T. Propolis-induced granulomatous contact dermatitis accompanied by marked lymphadenopathy. British Journal of Dermatology 2001;144:1277-1278. PubMed Caso clinico
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Monografia di Health Canada del 30 maggio 2025

    PROPOLIS Buccal

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are allergic to bee products, poplar tree products, or balsam of Peru (Brinker 2010; Marcucci 1995; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Gryzwa 1983).

    Fonti citate da Health Canada (5)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie 1995;26:83-89.
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Caso clinico
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condizione di applicazione: All products, except those not swallowed (e.g., gargles, rinses).

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.

    Reazioni avverse note

    Stop use if hypersensitivity/allergy occurs (PPRC 2020; Scully 2006; Hsu et al. 2004; Teraki and Shiohara 2001; Machácková 1988; Hausen et al. 1987; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Grzywa 1983).

    Fonti citate da Health Canada (8)
    • Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy (II): the sensitizing properties of 1,1-dimethylallyl caffeic acid ester. Contact Dermatitis 1987;17:171-177. PubMed Caso clinico
    • Hsu CY, Chiang WC, Weng TI, Chen WJ, Yuan A. Laryngeal edema and anaphalactic shock after topical propolis use for acute pharyngitis. American Journal of Emergency Medicine 2004;22(5):432-433. PubMed Caso clinico
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Caso clinico
    • PPRC 2020: Pharmacopoeia of the People’s Republic of China, Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People’s Republic of China; 2020.
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Scully C. Propolis: A background (Letter). British Dental Journal 2006;200(7):359-360. PubMed
    • Teraki Y, Shiohara T. Propolis-induced granulomatous contact dermatitis accompanied by marked lymphadenopathy. British Journal of Dermatology 2001;144:1277-1278. PubMed Caso clinico
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Monografia di Health Canada del 29 maggio 2026

Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.

Marca : Gayelord Hauser

Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.

Invio per analizzare, Maiusc+Invio per una nuova riga